SMA Data Endears IONS To Investors, PFE Opens Wallet, Busy Months Ahead For DRRX

Shares of Ionis Pharmaceuticals Inc. (IONS) rose over 30% on Monday, following encouraging data from its phase III trial of Nusinersen in infantile-onset spinal muscular atrophy.

from RTT - Biotech http://ift.tt/2aO7Ngi
via IFTTT